Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7711338 | 1.00 | PARP1 (0.52) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL8119255 | 0.86 | PARP1 (0.43) | PARP1PDE3BPDE3ASMYD3ALOX5 | |
| SCHEMBL6994006 | 0.84 | ALOX5 (0.36) | PARP1ALOX5KDM4EFDPS | |
| SCHEMBL6998657 | 0.81 | PARP1 (0.59) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL5188341 | 0.80 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL532347 | 0.80 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL5342897 | 0.80 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL6999641 | 0.79 | PARP1 (0.49) | PARP1PDE3BPDE3ASMYD3 | |
| SCHEMBL531954 | 0.79 | ALOX5 (0.55) | PARP1PDE3BPDE3ASMYD3ALOX5 | |
| SCHEMBL6999639 | 0.79 | PARP1 (0.49) | PARP1PDE3BPDE3ASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |